Healix, a Sugar Land, TX-based provider of outsourced alternate-site infusion therapy management services, received a growth investment from TA Associates.
The financial terms of the transaction were not disclosed. In conjunction with TA’s investment, Brit Pim has joined Healix as the company’s new Chief Executive Officer while Emily C. McGinty, a Senior Vice President at TA Associates, and Jennifer M. Mulloy, a Managing Director at TA Associates, will join the Board of Directors.
The investment will support the company’s growth.
Founded in 1989 by Alan Chaveleh and Mort Baharloo, Healix is a provider of infusion therapy management services and compounded intravenous pharmaceuticals for physician practices and hospitals.
The company manages office infusion centers on behalf of physicians, hospitals and medical institutions, supporting outpatient treatment for optimal patient comfort and care. Healix also offers central pharmacy services, with patient-specific compounding from a 503A licensed pharmacy facility.